Strategic Advocates LLC Editas Medicine, Inc. Transaction History
Strategic Advocates LLC
- $384 Billion
- Q3 2025
A detailed history of Strategic Advocates LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Strategic Advocates LLC holds 1,077 shares of EDIT stock, worth $2,800. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,077Holding current value
$2,800% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding EDIT
# of Institutions
226Shares Held
46.2MCall Options Held
841KPut Options Held
304K-
Black Rock Inc. New York, NY7.78MShares$20.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.97MShares$18.1 Million0.0% of portfolio
-
Nuveen, LLC Charlotte, NC2.09MShares$5.44 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.04MShares$5.3 Million0.0% of portfolio
-
State Street Corp Boston, MA1.93MShares$5.01 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $179M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...